The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.

Some cats wobble, fall over constantly, and generally have no control over their movements. These cats live with the ...

(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its ...

Larimar Therapeutics ( ($LRMR) ) has provided an update. On November 10, 2025, Larimar Therapeutics announced an updated slide presentation ...

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.

After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch next. Click here to read more.

A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...

Regulators upheld their earlier decision after reexamination, saying the substance does not meet the criteria for new active ...